Use of CGM in Kidney Transplant Recipients
Recruiting · NCT04783441 · Interventional (participants receive a specific treatment) · Lead sponsor: University of California, Davis
View the official record on ClinicalTrials.gov →Interventions studied
Dexcom G6Dexcom G6 blinded sensor
What this trial is about
The investigators want to study the impact CGM (continuous glucose monitoring) has on patients glycemic control as determined by time in range (TIR 70-180 mg/dL) in the Diabetic Kidney Transplant population.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age 18 or above
- Received a kidney transplant within the past year with functioning kidney (eGFR \> 30 mL/min
- Person with Type 2 Diabetes and on insulin
- Access to home wi-fi connection
Exclusion criteria
- Person with Type 1 Diabetes
- Patients taking hydroxyurea
- Patient unable to wear the Dexcom G6 device at all times for any reason
- Must be able to test blood glucose with meter 4x a day when on blinded CGM.
- Presence of clinically significant visual or cognitive impairment
- Illiterate
- Prisoners
- Women who are pregnant, who plan to become pregnant during the course of the study, or who are breastfeeding
- Presence of clinically unstable cardiovascular disease
- Active malignancy treatment
Where it is running
1 location listed across 1 US state.
- UC Davis Health - Sacramento, California, United States